Phase 2 Head and Neck Squamous Cell Carcinoma (HNSCC) Clinical Trials

14 recruitingPhase 2

What is a Phase 2 trial?

Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.

Phase 2 Head and Neck Squamous Cell Carcinoma (HNSCC) Clinical Trials

What is a Phase 2 trial?

Nimotuzumab Combined With PD-1 Inhibitors and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma

[68Ga]Ga-FAPI-46 in Staging of Head and Neck Carcinomas

A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

Window of Opportunity in Preserving Laryngeal Function Trial

Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC

Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

A Study of MT-4561 in Patients With Various Advanced Solid Tumors

INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC

AK129 Combination Therapy for Advanced Solid Tumors

Tislelizumab Combined With SBRT for the Treatment of Head and Neck Squamous Cell Carcinoma

A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies

Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, as First-line Treatment for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Patients With a PD-L1 Combined Positive Score (CPS)≥1≤19.